



ASX Announcement | 24 April 2024 AdAlta Limited (ASX:1AD)

NOTICE OF LISTED OPTIONS AND EXERCISE INSTRUCTIONS

AdAlta Limited (ASX:1AD) (“**AdAlta**” or “**the Company**”) notes that the Company has 173,065,186 listed options on issue (ASX:1ADOA) (**Listed Options**). The exercise price of the Listed Options is \$0.03 per option and the expiry date for their exercise is 29 May 2024 (**Expiry Date**).

The Company wishes to inform the holders of the Listed Options that they can exercise all or part of their Listed Options prior to the Expiry Date by providing the Company:

1. A completed exercise notice specifying the number of Listed Options being exercised; and
2. Payment of funds for the total exercise price for the number of Listed Options being exercised.

Holders can log into their accounts on the [Automic Investor Portal](#) to access the option-exercise forms.

Once logged in, click on “Documents and Statements.” Select “Other Documents,” then download the 1ADOA Option Exercise Form. Holders can exercise their options by using BPAY or EFT. Holders who would prefer to use cheque, please contact the Company on (+61) 3 9479 5159.

Holders are reminded that Options are only able to be exercised a minimum of 100,000 at a time (unless the holder has less than that number).

If you are a Holder and have any questions regarding the expiry of the Listed Options or their exercise, please contact the Automic Registry on:

Phone: 1300 288 664; or

Email: hello@automic.com.au.

This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries
The Capital Network
Russell Katz
P: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body® technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. The Company is advancing partnering discussions to finance Phase II clinical studies, preparation for which is underway.

The Company is also entering collaborative partnerships to advance the development of its i-body® platform and expand its clinical stage pipeline. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta's i-body® technology.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

For more information



Join our [InvestorHub](#)



Follow us on [Twitter](#)



Follow us on [LinkedIn](#)

To learn more about AdAlta please click here: www.adalta.com.au

24 April 2024

Dear Option Holder

IMPORTANT INFORMATION / ACTION REQUIRED

EXPIRY OF LISTED OPTIONS (ASX: 1ADOA)

We are writing to you as a registered holder of listed options (ASX: 1ADOA) (**Listed Options**) in AdAlta Limited (**AdAlta or Company**) to remind you that the Options will expire at 5:00pm (AEST) on 29 May 2024 (**Expiry Date**).

Instructions

There is no obligation upon Option holders to exercise their Options. The courses of action available to you as a holder of these soon to expire Options are:

- a) Exercise your Options: If you wish to exercise your Options, you must complete the “Notice of Exercise of Options” (Notice of Exercise) form accompanying this letter and provide the completed Notice of Exercise together with payment of \$0.03 per Option being exercised in accordance with the instruction set out in the Notice of Exercise. Your completed Notice and payment (in cleared funds) must be received by no later than 5:00pm (AEST) on the Expiry Date. Instructions regarding methods of payment are included in the Notice of Exercise.

Holders can also log into their accounts on the Automatic Investor Portal to access the option-exercise forms. Once logged in, click on “Documents and Statements.” Select “Other Documents,” then download the 1ADOA Option Exercise Form.

Holders can exercise their options by using BPAY or EFT. Holders who would prefer to use cheque, please contact the Company on (+61) 3 9479 5159.

You are reminded that Options are only able to be exercised a minimum of 100,000 at a time (unless the holder has less than that number).

- b) Sell your Options: Please note that official quotation of the Options on ASX will cease at close of trading on 23 May 2024, being four business days before the Expiry Date.
- c) Do nothing and allow your Options to expire: If you do not exercise or sell your Options in the manner described above, they will expire at 5:00pm (AEST) on the Expiry Date and your right to subscribe for fully paid ordinary shares in the capital of the Company (Shares) at \$0.03 per Share will lapse.

In accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, the Company provides the following information:

- a) the name of the holder of the Options, the number of Options held and the number of Shares to be issued on exercise of the Options is set out in the personalised Notice of Exercise accompanying this letter;
- b) the exercise price of the Options is \$0.03 per Option;
- c) the Options must be exercised and payment (in cleared funds) received by no later than 5:00pm (AEST) on 29 May 2024 (being the Expiry Date);
- d) if you do not exercise (or sell) your Options in the manner described above, they will expire at 5:00pm (AEST) on the Expiry Date and your right to subscribe for Shares at \$0.03 per Share will lapse;
- e) official quotation of the Options on ASX will cease at close of trading on 23 May 2024, being four business days before the Expiry Date;
- f) the market price of Shares on ASX on 23 April 2024 was \$0.029, being the closing price of Shares on ASX prior to the date of this letter;
- g) during the 3 months preceding the date of this letter:
 - i. the highest market sale price of Shares on ASX was \$0.036 on 8 April 2024; and
 - ii. the lowest market sale price of Shares on ASX was \$0.019 on 5 February 2024.
- h) as at the date of this notice, there are no underwriting agreements in relation to the Options.

If you have any questions in relation to any of the above, please contact the Company on
+61 3 9479 5159

Yours sincerely,


Tim Oldham
CEO and Managing Director
AdAlta Limited

SRN/HIN: [HolderNumberMasked]
Security Code: 1ADOA
Number of Options held: [1ADOAHolding]
Option Expiry Date: 29 May 2024
Exercise Price: \$0.03
Total Amount payable (exercising in full): [Pay]

Notice of Exercise of Options

I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. New Options will only be able to be exercised in a minimum number of 100,000 options at a time (unless the holder holds less than that number, at which time the minimum number of options able to be exercised will be the number held). Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. I/We agree to accept such Shares subject to the Constitution of AdAlta Limited.

1. Number of Options to be Exercised <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Total payment required @ \$0.03 per Option A\$ <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> , <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>
If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down.	

2. Payment: You can pay either by BPAY®, EFT	
Option A – BPAY®  Biller Code: Ref No: <small>© Registered to BPAY Pty Ltd ABN 69079137518</small>	Option B – Electronic Funds Transfer (EFT) The unique payment reference number which has been assigned to your Application is: [holderid]-9334-1ADOA Funds are to be deposited directly to following bank account: Account name: Account BSB: Account number: Swift Code: IMPORTANT: You must quote your unique reference number as your payment reference/ description when processing your EFT payment. Failure to do so may result in your funds not being allocated to exercise the Options and shares subsequently not issued. Note: You do not need to return this Form if you have made payment via EFT. Your unique payment reference number will process your payment to your Options exercise electronically.
Contact your financial institution to make your payment from your cheque or savings account. Note: You do not need to return this form if you have made payment via BPAY®. Your BPAY® reference number will process your payment to your Options exercise electronically. You should check the processing cut-off time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Share Registry in time.	

3. Contact details	
Telephone Number (<input type="text"/>) <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Contact Name (PLEASE PRINT) <input type="text"/>
Email Address <input type="text"/>	
SUPPORT YOUR COMPANY: By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).	